Grundinformationen
- Standard-SMILES
Cc1cccc(N2CC(CO)OC2=O)c1- InChIKey
MXUNKHLAEDCYJL-UHFFFAOYSA-N- Summenformel
- C11H13NO3
- Durchschnittliche Molmasse
- 207,23 g/mol
- Monoisotopische Masse
- 207,08954328
Überblick
5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one is a member of the class of oxazolidinones that is 5-(hydroxymethyl)-1,3-oxazolidin-2-one substituted by a 3-methylphenyl group at position 3. It is a primary alcohol, a member of toluenes and an oxazolidinone.
Namen und Bezeichner
- Bevorzugter Name
- Toloxatone
- IUPAC
- 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one
- Lokaler Name
- Toloxaton
- Englischer Name
- Toloxatone
- Summenformel
- C11H13NO3
- Molmasse
- 207.23
Namen und Synonyme
Weitere Namen anzeigen
Datenbank-Bezeichner
- CAS
29218-27-7- PubChem CID
- 34521
- DTXSID
DTXSID40865478- ChEMBL
CHEMBL18116- ChEBI
CHEBI:156575- UNII
- 5T206015T5
- EC Number
- 249-522-2
- Nikkaji
- J21.701H
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 1,2
- Polarare Oberfläche (TPSA)
- 49,8 Ų
- H-Brücken-Donoren
- 1
- H-Brücken-Akzeptoren
- 3
- Frei drehbare Bindungen
- 2
- Schwere Atome
- 15
- Formalladung
- 0
- Komplexität
- 244
Physikochemische Eigenschaften
- Schmelzpunkt
- 76 ° · 76°
- Siedepunkt
- 358.9 · 358.9±21.0 °C(Predicted)
- Dichte
- 1.245 · 1.245±0.06 g/cm3(Predicted)
- storage temp.
- 2 · Inert atmosphere,2-8°C
- Löslichkeit
- 10 mg/mL · DMSO: >10mg/mL
- Aggregatzustand
- solid
- pka
- 14.05 · 14.05±0.10(Predicted)
- Farbe
- White to off-white
- InChI
- 1S/C11H13NO3/c1-8-3-2-4-9(5-8)12-6-10(7-13)15-11(12)14/h2-5,10,13H,6-7H2,1H3
- InChIKey
- MXUNKHLAEDCYJL-UHFFFAOYSA-N
- SMILES
- Cc1cccc(c1)N2CC(CO)OC2=O
Sicherheit und Regulatorisches
GHS-Klassifizierung
GHS Classification
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 39 reports by companies from 1 notifications to the ECHA C&L Inventory.
Gefahrenhinweise
Sicherheitsdaten
- wgk
- 3
- ridadr
- 3249
- RTECS-Nr.
- RQ2867500
- risk_code
- 22
- Toxizität
- LD50 orally in mice (mg/kg): 1850 (Fauran); also reported as 1500 (Raynaud)
- hazard_code
- Xn
- hazard_class
- 6.1(b)
- packing_group
- III
- Speicherklasse
- 11 - Combustible Solids
- Hazard Classifications
- Acute Tox. 4 Oral
Chemie und Industrie
Pharmakologische Informationen
ATC Code
N - Nervous system
QN - Nervous system
Mechanism of Action
This medication is a reversible inhibitor of monoamine oxidase type-A (also known as RIMA). MAO-A can be found in norepinephrinergic and serotonergic neurons and regulates the metabolism of serotonin and catecholamines, allowing for increased circulation in the synaptic cleft. Traditional monoamine oxidase inhibitors irreversibly inhibit monoamine oxidase and therefore, side effects, drug interactions, and food interactions persist as long as 2-3 weeks after discontinuing toloxatone. The elevation of serotonin and norepinephrine levels occurs rapidly after medication administration. However, the therapeutic relief of depressive symptoms requires weeks of daily treatment to observe results. Selective and reversible MAO-A inhibitors are more effective in treating major depression without several of the drug and food interactions associated with traditional monoamine oxidase inhibitors.
MeSH Pharmacological Classification
Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.
A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414)
Absorption, Distribution and Excretion
Mainly hepatic 1% of drug is excreted unchanged in the urine
High hepatic excretion rate
Anwendungen
BeschreibungToloxatone is a selective, reversible and competitive inhibitor of type A monoamine oxidase (MAO-A) which shows clinical utility as an antidepressant. It is reportedly free of the "cheese effect" in man, possibly due to the reversible nature of its inhibitory effect on intestinal MAO-A in the presence of high concentrations of tyramine.
VerwendenToloxatone is a monoamine oxidase-A (MAO-A) inhibitor.
Vor- und nachgelagerte Produkte
Vorgelagerte Rohstoffe
Anbieter35 Anbieter
Zugehörige Reaktionen
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Verknüpfte Notizen
Wird geladen…